Navigation Links
AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
Date:2/8/2008

MINNEAPOLIS, Feb. 8 /PRNewswire/ -- AGA Medical today issued the following response to a press release distributed on February 7, 2008 regarding a purported victory Occlutech GmbH had achieved in the AIPPI in AGA's patent dispute with Occlutech. The release suggested that a proceeding of some sort was conducted before the AIPPI and that organization agreed with the Occlutech position. That suggestion is false and misleading. AGA has not been involved in any proceedings with Occlutech in which AIPPI has been involved. AIPPI has not contacted AGA for its comments on any matter.

According to its charter, AIPPI is characterized as a trade and professional association and not an adjudicatory body. AIPPI does not seem to engage in any arbitration work. AIPPI is not the "European International Association for the Protection of Intellectual Property" as Occlutech claims, but is simply the International Association for the Protection of Intellectual Property, having no connection with any European governmental entity.

The facts are as follows: after being found to be an infringer of AGA's patent in Germany, Occlutech has made two attempts to stay enforcement in Germany, both of which were unsuccessful. They made an unsuccessful attempt to obtain a ruling of non-infringement/invalidity in Italy that did not succeed. In addition, Occlutech has been found guilty of violating the Court order on infringement in Germany and was fined by the court. The injunction of the German court remains in place.

Additionally, AGA Medical is exploring remedies under German law that might be available to prevent such misrepresentations from continuing.

ABOUT AGA MEDICAL: AGA Medical Corporation, based in Plymouth, Minnesota (just outside Minneapolis) is the leader in developing interventional devices to treat structural heart defects. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The company is expanding into new areas such as the minimally invasive repair of vascular abnormalities. Over 790 articles have been published in peer reviewed medical publications that support the benefits of AGA Medical devices including improved patient outcomes, reduced length of stay and accelerated recovery times for the patient, AGA Medical devices have received regulatory approval and are marketed in over 100 countries with over 278,000 devices shipped to date. For more information visit http://www.amplatzer.com.

MEDIA CONTACT:

Devin Nagy

Brunswick Group LLC

202.393.7337

dnagy@brunswickgroup.com


'/>"/>
SOURCE AGA Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
2. BioMS Medical to present at BIO CEO & Investor Conference
3. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
4. Linc Facility Services Acquires Morse Medical
5. Perrigo Company to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Covance to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program
8. Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
9. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
10. Medical University of South Carolina Opens State-of-the-Art Facility
11. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an innovation leader ... & Technologien GmbH, thereby expanding its product portfolio to include allergy and food ... asthma, atopic eczema or a food allergy. Allergies are escalating to epidemic proportions ...
(Date:6/22/2017)... Prussia, PA (PRWEB) , ... June 22, 2017 ... ... knowledge and superior results to clients throughout the biopharma and life sciences industries, ... changes the industry is seeing. Tunnell’s Kip Wolf will be speaking on “The ...
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to announce ... determined to be appropriate as a screening test at dairies and farms for raw ... system, and the Charm EZ Lite system. These systems are a combination incubator and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... determine the adulterants which pose the most likely threat to their products at ... this year. , IFT's annual food expo attracts over 20,000 attendees representing ...
Breaking Biology Technology:
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
Breaking Biology News(10 mins):